SEATTLE, Sept. 19 /PRNewswire/ -- Immunex Corporation (Nasdaq: IMNX) has
tapped Ms. Kimberly Ives, to head its Finance Department, the company
announced today. Serving as vice president, finance, Ms. Ives will run the
strategic financial analysis, planning and daily operations of the finance and
accounting departments, reporting to Immunex chief financial officer and
senior vice president, David Mann.
Ms. Ives, 39, joins Immunex after 13 years in global finance and senior
management with Atlantic Richfield Company (ARCO) (acquired by BP Amoco in
April of 2000). She most recently served as vice president, finance, planning
and control for ARCO Products Company.
"As Immunex continues to evolve into a major provider of health care
products and a leader in pharmaceutical research and development, we continue
to broaden our management depth and breadth," said Mann. "Kimberly's
experience and leadership promise to contribute significantly to our capacity
to operate efficiently, while positioning the company for long-term growth."
Ms. Ives is a graduate of Stanford University. She earned her MBA at the
University of California, Los Angeles.
Immunex Corporation is a biopharmaceutical company dedicated to improving
lives through immune system science innovations.
American Home Products Corporation owns a majority interest in Immunex.
AHP is one of the world's largest research-based pharmaceutical and health
care products companies. It is a leader in the discovery, development,
manufacturing and marketing of prescription drugs, including biotechnological
and vaccine products, animal health care products and over-the-counter
medications.
NOTE: This news release contains forward-looking statements that involve
risks and uncertainties, including risks associated with clinical development,
regulatory approvals, our reliance on third-party manufacturers, product
commercialization and other risks described from time to time in the SEC
reports filed by Immunex, including the most recently filed Form 10-Q. An
electronic version of this news release -- as well as additional information
about Immunex of interest to investors, customers, future employees and
patients -- is available on the Immunex home page at http://www.immunex.com.
SOURCE Immunex Corporation
 back to top
Related links:
http://www.immunex.com
Company News On-Call:
http://www.prnewswire.com/comp/434644.html or fax,
800-758-5804, ext. 434644
CONTACT:
media, Tim Warner, 206-470-4193, or
investors, Mark Leahy, 206-389-4363, both of Immunex Corporation
|
